Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
by Zacks Equity Research
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $68.22, moving +0.78% from the previous trading session.
Top Stock Reports for JPMorgan, Intel & McDonald's
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Intel (INTC), and McDonald's (MCD).
Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?
by Zacks Equity Research
Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $68.86, moving +1.37% from the previous trading session.
Gilead's (GILD) Kite Announces Positive Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.
Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $67.18 in the latest trading session, marking a +0.8% move from the prior day.
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.
Should You Buy Biotech ETFs Now?
by Neena Mishra
Biotech stocks are rallying this month; can the trend continue?
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19
by Zacks Equity Research
Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $68.77 in the latest trading session, marking a -0.75% move from the prior day.
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $67.43 in the latest trading session, marking a +1.43% move from the prior day.
Intercept (ICPT) Ocaliva's Prescribing Information Updated
by Zacks Equity Research
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider Q1 loss on increased R&D expenses.
Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales
by Zacks Equity Research
Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.
Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.